The past 40 years have brought great advances in the knowledge of morphology, immunology and epidemiology of fungal infections in man. Each general advance in the science of medicine has had its counterpart in man's improved facility to deal with these infections therapeutically. Although satisfactory control of fungal infections of man is still lacking, productive paths of investigation seem to have been found and the continued application of rigorous discipline to research efforts should provide even more efficient treatment in the future.
Summary
The past 40 years have brought great advances in the knowledge of morphology, immunology and epidemiology of fungal infections in man. Each general advance in the science of medicine has had its counterpart in man's improved facility to deal with these infections therapeutically. Although satisfactory control of fungal infections of man is still lacking, productive paths of investigation seem to have been found and the continued application of rigorous discipline to research efforts should provide even more efficient treatment in the future.
IN SPITE of the emphasis being placed by this conference on the therapy of fungal diseases it seems to me that the understanding of where we have been and to what point we have arrived in the treatment of this group of diseases requires us to consider the broader accomplishments of our quest for understanding of our subject. That is to say that a simple recitation of what drugs, incantations, and manipulations were used and are being used and the names and drinking habits of the men who first published on these activities simply will not do. If perspective is desired then a search for understanding is essential.
I have been unable to find any citation or letters to the editor to explain the rationale of what must have been the earliest treatment by our ancestors of itchy toes; that is amputation. Nevertheless, I believe that it is clear to us all what motivated the action.
On the other hand Hippocratic logic in using local bleeding as treatment for ulcers on the toes occasionally caused by fungi is a bit obscure unless one accepts the master's rationale that bleeding an area is a means to dry it (Adams, 1971 (Blank and Roth, 1959 (Schoenbach and Greenspan, 1948; Schoenbach et al., 1951 (Snapper and McVay, 1952 (Brown and Hazen, 1949; Hazen and Brown, 1950) . The former was useful in its own right but the primary discovery was that a polyene substance had unique properties, among them its ability in low concentration to inhibit the growth of several fungi in vitro and, in high concentrations, to kill them. The good news was that in vitro the spectrum included Candida spp., Cryptococcocus neoformans, Histoplasma capsulatum, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Sporothrix schenckii (these latter in their yeast forms) and a wide variety of the dermatophytes. The bad news was that the substance was all but completely insoluble in water and, therefore, its use was limited to direct application to the offending fungus.
Never mind, this was a major discovery both from the point of view of the direct results over the years of use of nystatin and from the fact that it introduced to the investigator a new family of substances that has proved to be highly effective in the treatment of deep fungus infections in man. Keeping in mind the time of the discovery we find ourselves in the halcyon days of the post-World War II search for new antibiotics.
In addition to the contribution made to the treatment of Candida infections, nystatin has become a tool to unravel the mode of action of polyene antibiotics on the susceptible micro-organisms. Lampen and his colleagues (Lampen, Morgan and Slocum, 1956, 1957) pointed out that nystatin attaches itself to the cell wall of the yeast cell and renders it more permeable, first increasing its 02 consumption and then causing it to fall to nothing, with subsequent cell death. This latter appeared to be due to loss of potassium through the permeable cell membrane followed by inhibition of utilization of glucose both via aerobic and anaerobic pathways (Marini, Arnow and Lampen, 1961) . As a clinician, my own interests were more in the area of deep fungus infections; thus I found nystatin disappointing but in the area of surface troubles with Candida in debilitated patients, for example, the effects of this substance were amazing. It was always my feeling that it lacked only a colourful personality such as that of gentian violet, the treatment of another era for Candida overgrowth. I probably was not the first to realize that a few drops of gentian violet added to the suspension of nystatin applied to tongue, mouth, ear, finger-tips or vaginal mucosa added tremendously to the impact of the treatment on the patient. Now the stage was set for the discovery by Gold, et al. (1956) (Symmers, 1973 (Gruneberg, Titsworth and Bennet, 1964) .
I remember a meeting of the Cooperative Study group of the Veterans Administration dealing with fungus diseases in the early 1960s when Dr Gruneberg mentioned his discovery; and, in the 6 months between that first announcement and our next meeting, several investigators reported anecdotal experience with the drug. I complained to my colleagues that it was too bad that no animal work was being done to support these early in vitro claims and in the manner of many a dyspeptic non-believer, doubted the validity of the claims. As matters have turned out I was wrong in my conclusions even though I am convinced that my methodological complaints were justified. We have come to find 5-fluorocytosine a useful adjunctive drug to be used with amphotericin B in the treatment particularly of cryptococcal meningitis. It is useful in its own right as a treatment for candidal infections but in the case of both Candida and Cryptococcus resistance develops quickly, or is already present, and this limits the use of the agent as a single treatment.
Coming along as it did as a by-product of cancer chemotherapy, we must credit the zealous search for anti-neoplastic agents as being responsible for the discovery of 5-fluorocytosine. That was an interesting time, when millions of U.S. dollars were being spent in the race to find the cure for malignant disease. In the course of studies with this agent we learned that the effect on the yeast cell was actually achieved by 5-fluorouracil and the conversion of 5-fluorocytosine to 5-fluorouracil occurred within the yeast cell. This conversion does not occur within the human cells because man lacks the necessary enzyme, a very convenient difference between yeast and human cells indeed! This, then, accounts for the relative lack of toxicity in man of this drug and rationalizes its use against yeast infections.
This brings us to a family of drugs that has appeared since 1969. Clotrimazole and miconazole
were both reported upon in those times (Plempel et al., , 1970 Godefroi et al., 1969 Such a 'crafty' approach was too much even for the V.A. and saramycetin faded away and has not been heard of since. We must always wonder what might have been but, frankly, the early results were no better than with existing treatment so perhaps we didn't lose too much.
Of even more personal connection was the story of hamycin, a polyene antibiotic that was discovered in India by Thirumalachar, Menon and Bhatt (1961) and developed in the U.S. by Williams, Bennett and Emmons (1965) . The drug was found to be active against B. dermatitidis and in clinical practice was found to be a potential alternative to amphotericin B and hydroxystilbamidine in the treatment of North American blastomycosis. The preliminary work was done and the drug was accepted by the Food and Drug Administration for clinical trials. Again the V.A. was involved and it was my responsibility to develop the protocol and help to organize the co-operating hospitals. I spent nearly a year getting things into good order and had arranged for the final protocol to be printed by the V.A. with the blessings of the statisticians. As a courtesy I sent the last rough copy to the drug company representatives with whom I had been working closely. After a long silence, I was told that the company was discontinuing importation of the drug because the potential market did not seem to them to justify the cost. Who knows what we may have lost and who can say what we might have learned about cell-drug interaction or dynamics of organism biochemistry.
We are about to embark on a conference to hear the latest news. What has gone before was a reflection of the needs, the times but especially the curiosity and industry of the men who did the work. I have not in any way cited all the major contributions made in this field but I have tried to pick out some of the early discoveries. There is an American bias to this presentation but for this I have no excuses, only an explanation. This is but a preamble to the conference. The one matter which we can apply from past experience to future activity is the rigorous insistence on careful dissemination of data and, even more, a careful interpretation of them.
As we open this conference my clinical bias prompts me to express questions which I hope may be touched upon. Are there in vitro indices which can be used as guides to the length of antifungal therapy? Are all known fungal infections necessarily to be treated with anti-fungal agents? Is the host response a matter of only divine intervention, or may we expect more effective and longer lasting tools such as transfer factor, B.C.G., levamisole and thymic hormone to be available to the clinician? Is immunization a means significantly to reduce morbidity and mortality from fungal infections?
